share_log

Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $30

Benzinga ·  Aug 13 19:19  · Ratings

Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from $28 to $30.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment